Annette Colin - Boule Diagnostics VP CFO
Insider
Annette Colin is VP CFO of Boule Diagnostics AB
| Phone | 46 87 44 77 00 |
| Web | https://www.boule.com |
Boule Diagnostics Management Efficiency
The company has return on total asset (ROA) of 0.0271 % which means that it generated a profit of $0.0271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0335 %, meaning that it generated $0.0335 on every $100 dollars invested by stockholders. Boule Diagnostics' management efficiency ratios could be used to measure how well Boule Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Boule Diagnostics AB has accumulated 50.6 M in total debt with debt to equity ratio (D/E) of 46.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Boule Diagnostics has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Boule Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Boule Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Boule Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Boule to invest in growth at high rates of return. When we think about Boule Diagnostics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Maja Nilsson | Biotage AB | N/A | |
| Ola Haggfeldt | CTT Systems AB | 54 | |
| Lars Levin | C Rad AB | 52 | |
| Maria Wester | CTT Systems AB | 57 | |
| Peter Landquist | CTT Systems AB | 65 | |
| Yve Thorenburg | CellaVision AB | 65 | |
| Tim Thurn | C Rad AB | 42 | |
| Raffaella Bombarda | Biotage AB | 49 | |
| Petra Duprez | Biotage AB | 58 | |
| JonSverre Schanche | Biotage AB | 66 | |
| Nina Wallander | CellaVision AB | 49 | |
| Jonas Stahlberg | Biotage AB | 48 | |
| Olof Nord | Biotage AB | 48 | |
| CS BSc | Biotage AB | 50 | |
| Scott Carr | Biotage AB | 56 | |
| Simon Ostergaard | CellaVision AB | 52 | |
| Markus Berg | CTT Systems AB | 43 | |
| Maths hc | CellaVision AB | 57 | |
| Julien Veyssy | CellaVision AB | 40 | |
| Xiaodong Wang | C Rad AB | 44 | |
| Tony Rosendal | CTT Systems AB | 56 | |
Management Performance
| Return On Equity | 0.0335 | |||
| Return On Asset | 0.0271 |
Boule Diagnostics Leadership Team
Elected by the shareholders, the Boule Diagnostics' board of directors comprises two types of representatives: Boule Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boule. The board's role is to monitor Boule Diagnostics' management team and ensure that shareholders' interests are well served. Boule Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boule Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annette Colin, VP CFO | ||
| Helena Borjesson, Chief Officer | ||
| Kiarash Farr, Director of Commercial Operations | ||
| Karen Bornstein, North Marketing | ||
| Aishat Bislieva, VP Culture | ||
| Jesper Soderqvist, CEO Pres | ||
| Mikael Ekholm, VP Production | ||
| Michael Eliott, Head Consumables | ||
| Mattias Isaksson, VP Marketing | ||
| Christina Hugosson, Head Systems |
Boule Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boule Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0335 | |||
| Return On Asset | 0.0271 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 562.26 M | |||
| Shares Outstanding | 38.83 M | |||
| Shares Owned By Insiders | 12.64 % | |||
| Shares Owned By Institutions | 27.69 % | |||
| Price To Earning | 24.26 X | |||
| Price To Book | 1.06 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Boule Stock Analysis
When running Boule Diagnostics' price analysis, check to measure Boule Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boule Diagnostics is operating at the current time. Most of Boule Diagnostics' value examination focuses on studying past and present price action to predict the probability of Boule Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boule Diagnostics' price. Additionally, you may evaluate how the addition of Boule Diagnostics to your portfolios can decrease your overall portfolio volatility.